A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

Cell

Volumn 137, Issue 1, 2009, Pages 87-98

  Adorno, Maddalena ^a   Cordenonsi, Michelangelo ^a   Montagner, Marco ^a   Dupont, Sirio ^a   Wong, Christine ^b   Hann, Byron ^b   Solari, Aldo ^c   Bobisse, Sara ^c   Rondina, Maria Beatrice ^c   Guzzardo, Vincenza ^c   Parenti, Anna R ^c   Rosato, Antonio ^c,d   Bicciato, Silvio ^d,e   Balmain, Allan ^b   Piccolo, Stefano ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

SIGNALING

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; PROTEIN P63; RAS PROTEIN; SMAD PROTEIN; TERNARY COMPLEX FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

EID: 63049136592     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.01.039     Document Type: Article

References (22)

1. Bernards R., and Weinberg R.A. A progression puzzle. Nature 418 (2002) 823
2. Caulin C., Nguyen T., Lang G.A., Goepfert T.M., Brinkley B.R., Cai W.W., Lozano G., and Roop D.R. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J. Clin. Invest. 117 (2007) 1893-1901
3. Cordenonsi M., Dupont S., Maretto S., Insinga A., Imbriano C., and Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113 (2003) 301-314
4. Cordenonsi M., Montagner M., Adorno M., Zacchigna L., Martello G., Mamidi A., Soligo S., Dupont S., and Piccolo S. Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 315 (2007) 840-843
5. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., and Akhurst R.J. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86 (1996) 531-542
6. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29 (2001) 117-129
7. Deyoung M.P., and Ellisen L.W. p63 and p73 in human cancer: defining the network. Oncogene 26 (2007) 5169-5183
8. Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., Martello G., Stinchfield M.J., Soligo S., Morsut L., et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136 (2009) 123-135
9. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., van't Veer L.J., and Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
10. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F., and Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373
11. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21 (2001) 1874-1887
12. Grunert S., Jechlinger M., and Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 4 (2003) 657-665
13. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., and Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005) 469-483
14. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., Lindahl T., Pawitan Y., Hall P., Nordgren H., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66 (2006) 10292-10301
15. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872
16. Oft M., Akhurst R.J., and Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4 (2002) 487-494
17. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., and Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119 (2004) 847-860
18. Sobin, L.H., Wittekind, C., and International Union against Cancer. (2002). TNM classification of malignant tumours, 6th ed. (New York, Wiley-Liss).
19. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98 (2001) 10869-10874
20. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98 (2006) 262-272
21. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1 (2001) 233-240
22. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277 (2002) 18817-18826